Precigen, Inc. (Nasdaq: PGEN) reported transformative second-quarter results on August 4, 2026, driven by accelerating commercial sales of PAPZIMEOS, its first FDA-approved therapy for adults with recurrent respiratory papillomatosis (RRP). Total revenue reached $55.0 million, more than doubling sequentially on the strength of $53.1 million in PAPZIMEOS net sales, propelling the company to its first quarterly profitability.
The results mark a pivotal shift from clinical-stage biotech to commercial-stage operator, supported by broad U.S. adoption, strong payer coverage, and seven-year market exclusivity.
| Metric | Q2 2026 Estimate | Q2 2026 Result | FY 2026 Estimate | FY 2026 Result / Guidance |
|---|---|---|---|---|
| Revenue | ~$28M | $55.0M (PAPZIMEOS $53.1M) | n/a | Continued sequential growth expected |
| EPS (GAAP) | ~ ($0.01) | $0.05 (beat by $0.06) | n/a | First quarterly profit |
| Operating Income | n/a | $22.6M | n/a | Positive |
| Gross Margin | n/a | ~95% ($52.2M gross profit) | n/a | Stabilize high-80s to low-90s after pre-launch inventory |
| Cash & Investments | n/a | $38.7M (+ $71.9M receivables) | n/a | Fund to cash-flow breakeven by YE 2026 |
| Patient Metrics | n/a | >500 hub enrollments; ~315M covered lives | n/a | Expanding centers & community use |
| Runway | n/a | Cash + receivables expected to bridge to breakeven | n/a | Self-funding trajectory |
Actual Results: First Quarterly Profitability and Explosive Product Launch
- Total revenues of $55.0 million, up dramatically from $0.9 million in the prior-year quarter, driven almost entirely by $53.1 million in PAPZIMEOS net product revenue (more than double the $21.6 million recorded in Q1 2026).
- Net income of $20.1 million, or $0.05–$0.06 per share — the company’s first quarterly profit since its strategic transformation into a healthcare company.
- Operating income of $22.6 million versus an operating loss in the year-ago period.
- Gross margin of approximately 95% ($52.2 million gross profit), reflecting the sale of lower-cost pre-launch inventory.
- Cash, cash equivalents, and investments of $38.7 million at quarter-end, supplemented by $71.9 million in trade receivables expected to be collected over the ensuing months.
- First-half 2026 total revenues reached $78.2 million with net income of $12.1 million.
Why It Matters: Commercial Inflection and Standard-of-Care Positioning
- PAPZIMEOS is rapidly establishing itself as the new standard of care for adult RRP, with patient hub enrollments exceeding 500 and expanding use across both major medical centers and community practices.
- Near-universal U.S. payer coverage (~315 million insured lives) and a permanent J-code effective April 1, 2026, have streamlined reimbursement and reduced site-of-care friction.
- FDA granted seven-year market exclusivity, providing protection against competition through August 2032.
- The EMA has validated and is reviewing the Marketing Authorization Application for Europe; pediatric expansion and redosing studies are underway.
- The sharp sequential revenue ramp and swing to profitability validate the commercial strategy and reduce reliance on external capital.
What’s Ahead: Sustained Growth and Pipeline Advancement
- Management expects continued sequential growth in PAPZIMEOS demand through the second half of 2026.
- Gross margins are projected to stabilize in the high-80% to low-90% range once remaining pre-launch inventory is sold.
- Existing cash, investments, and collection of receivables are expected to fund operations through cash-flow breakeven by year-end 2026.
- Pipeline updates, including data on PRGN-2009 in HPV-driven cancers, are planned by year-end, alongside ongoing global expansion efforts for PAPZIMEOS.
Risks to Forward Expectations: Launch Durability and Balance Sheet
- Revenue remains highly concentrated in a single product; any slowdown in new patient starts, adherence, or reimbursement could pressure results.
- Gross margins will moderate from the elevated 95% level as lower-cost inventory is depleted.
- Cash balance is modest relative to long-term debt (~$94 million); timely collection of receivables is important to the self-funding narrative.
- R&D spending is expected to rise as pipeline programs advance, which could offset operating leverage if commercial growth slows.
- Competitive or regulatory developments in RRP or related indications, and execution on European and pediatric expansions, remain key variables.
Bottom Line: Commercial Breakthrough Delivers Profitability
Precigen achieved a landmark quarter, converting the PAPZIMEOS launch into rapid sequential revenue growth and its first quarterly profit. Broad physician adoption, comprehensive payer coverage, and regulatory exclusivity provide a strong foundation for continued commercial momentum.
While the balance sheetA financial "snapshot" that reveals exactly what a company owns and owes at a specific moment in time. It follows the fundamental formula: Assets = Liabilities + Equity. By subtracting what is owed (liabilities) from what is owned (assets), the balance sheet shows the "book value" or the net worth belonging to the owners. More still requires careful management and margins will normalize, the results significantly de-risk the near-term story and position the company to potentially reach cash-flow breakeven by the end of 2026. Sustained patient uptake and successful pipeline progress will determine whether this inflection translates into durable long-term value..
